US8361977 — Compositions and methods for modulation of SMN2 splicing
Composition of Matter · Assigned to Isis Pharmaceuticals Inc · Expires 2030-12-23 · 5y remaining
What this patent protects
This patent protects compounds and compositions that modulate the splicing of SMN2 mRNA in cells, tissues, or animals, and their use in treating diseases and disorders.
USPTO Abstract
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.